leflunomide has been researched along with Spondylitis, Ankylosing in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 5.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| "In this open study of patients with active AS only those with peripheral arthritis improved significantly with leflunomide treatment." | 5.11 | Six months open label trial of leflunomide in active ankylosing spondylitis. ( Braun, J; Haibel, H; Rudwaleit, M; Sieper, J, 2005) |
| "Disease activity parameters for ankylosing spondylitis and lipid levels (total cholesterol, high-density lipoprotein cholesterol (HDLc) and triglycerides) were measured in 45 patients with ankylosing spondylitis for 6 months after starting treatment with leflunomide or placebo." | 2.72 | Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. ( de Koning, MH; Dijkmans, BA; Nurmohamed, MT; Peters, MJ; Twisk, JW; van de Stadt, RJ; van Denderen, JC; van der Horst-Bruinsma, IE; van der Paardt, M; van Halm, VP, 2006) |
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 1.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, L | 1 |
| Samanta, A | 1 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Haibel, H | 1 |
| Rudwaleit, M | 1 |
| Braun, J | 2 |
| Sieper, J | 2 |
| van Denderen, JC | 2 |
| van der Paardt, M | 2 |
| Nurmohamed, MT | 2 |
| de Ryck, YM | 1 |
| Dijkmans, BA | 2 |
| van der Horst-Bruinsma, IE | 2 |
| Maksymowych, WP | 1 |
| van Halm, VP | 1 |
| Peters, MJ | 1 |
| Twisk, JW | 1 |
| van de Stadt, RJ | 1 |
| de Koning, MH | 1 |
| Marzano, AV | 1 |
| Ramoni, S | 1 |
| Del Papa, N | 1 |
| Barbareschi, M | 1 |
| Alessi, E | 1 |
3 reviews available for leflunomide and Spondylitis, Ankylosing
| Article | Year |
|---|---|
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona | 2009 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
Novel therapies for ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Biomarkers; E | 2005 |
3 trials available for leflunomide and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Six months open label trial of leflunomide in active ankylosing spondylitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Ps | 2005 |
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
Topics: Adult; Aged; Antirheumatic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Leflunomide; Mal | 2005 |
Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Cholesterol, HDL; Double-Blind Me | 2006 |
2 other studies available for leflunomide and Spondylitis, Ankylosing
| Article | Year |
|---|---|
[Spondylarthritides].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono | 2006 |
Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Erythema Mu | 2008 |